At a glance
ClinicalIndex Comparison RecordN/ACompleted· 854 enrolled
Drug / intervention
bimatoprost 0.01%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
In Brief
An observational study evaluating bimatoprost 0.01% for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 854 participants across 1 site.
Detailed Summary
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesNetherlands
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
Primary CompletionDec 2010
First PostedJun 2012
TodayJul 2026
First PostedJun 27, 2012
Enrollment StartMar 1, 2010
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.0 years ago
Interventions
bimatoprost 0.01%drug
Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry